Quality assurance and standardization: summary of the satellite meeting, Turku, Finland, 11-12 June 1999

Area of Science:

• Biochemistry
• Clinical Chemistry
• Public Health

Background:

• Newborn screening programs require robust quality assurance (QA) for accurate results.
• The pre- and post-analytical phases are critical components of overall screening quality.
• Existing QA programs need to evolve to address multifaceted challenges in newborn screening.

Framework:

• Implementing multi-site screening programs necessitates specialized QA procedures.
• Developing and utilizing common reference materials, like amino acids, improves analytical quality and enables international comparisons.
• Accreditation of newborn screening programs is appropriate, with a focus on establishing criteria for pre- and post-analytical phases.

Implementation:

• New QA programs are being developed for regions like Latin America.
• Advanced QA initiatives include blind QA for amino acids and acylcarnitines using tandem mass spectrometry.
• Guidelines for specific screenings, such as congenital adrenal hyperplasia (CAH), are being established by professional societies.

Implications:

• Enhanced QA and standardization will improve the reliability and consistency of newborn screening globally.
• International collaboration on reference materials and QA protocols can lead to better health outcomes for newborns.
• The development of comprehensive QA frameworks will support the expansion and improvement of newborn screening services worldwide.